Evidence for the utility of cfDNA plasma concentrations to predict disease severity in COVID-19: A retrospective pilot study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00029389

Enrollment

Registered

2022-06-30

Start date

2022-07-04

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19

Interventions

Group 1: In bloodsamples of 22 patients cfDNA was experimentally measured at freely chosen time slots. Clinical outcome parameters are now to be correlated with these measurements. Group 2: cfDNA quan

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: between March and June 2020 hospitalized patients with COVID-19 infection

Exclusion criteria

Exclusion criteria: cancer

Design outcomes

Primary

Measure	Time frame
complications during course of disease and severity of disease graded by "WHO clinical progression scale"	—

Secondary

Measure	Time frame
SOFA score, duration of ICU stay, readmission to ICU, length of hospital stay, in hospital mortality	—

Countries

Germany

Contacts

Public ContactKatharina Hoeter

Klinik für Anästhesiologie der Universitätsmedizin Mainz

katharina.hoeter@unimedizin-mainz.de017663151835

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026